The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
This ia a single-arm, not-randomized, open-label phase II study. The purpose of this study is to evaluate the safety and efficacy of KN046 (PD-L1 /CTLA-4 Bispecific antibody) combined with Lenvatinib(TKI) for the treatment of advanced hepatocellular carcinoma.
HCC
BIOLOGICAL: KN046|DRUG: Lenvatinib
ORR, objective response rate (ORR) based on the RECIST 1.1 by investigator, 1 year after the last patient's enrollment
ORR, objective response rate (ORR) based on the mRECIST 1.1 and imRECIST respectively by investigator, 1 year after the last patient's enrollment|DCR, disease control rate (DCR) based on the RECIST 1.1，mRECIST 1.1 and imRECIST respectively by investigator, 1 year after the last patient's enrollment|DOR, duration of response (DOR) based on the RECIST 1.1，mRECIST 1.1 and imRECIST respectively by investigator, 1 year after the last patient's enrollment|TTR, time to response (TTR) based on the RECIST 1.1，mRECIST 1.1 and imRECIST respectively by investigator, 1 year after the last patient's enrollment|PFS, 1 year after the last patient's enrollment|OS-12m rate, 12-month overall survival rate, 1 year after the last patient's enrollment|OS, overall survival, 2 year after the last patient's enrollment
This ia a single-arm, not-randomized, open-label phase II study. The purpose of this study is to evaluate the safety and efficacy of KN046 (PD-L1 /CTLA-4 Bispecific antibody) combined with Lenvatinib(TKI) for the treatment of advanced hepatocellular carcinoma.